Add BrightSurf on Google Email

Valentin Fuster, MD, PhD, wins prestigious award from the International Atherosclerosis Society

Valentin Fuster, MD, PhD, has made significant contributions to the understanding of atherosclerosis through his research on inflammation, thrombosis, and treatment breakthroughs. His work has led to major advances in diagnosis and therapy, including the development of a cardiovascular 'polypill' that reduces cardiovascular mortality.

The heart has its own ‘brain’

Researchers at Karolinska Institutet and Columbia University identified a mini-brain within the heart with its own nervous system that controls the heartbeat. This discovery challenges current views on how the heartbeat is controlled and may lead to new insights into heart diseases and treatments.

SourceKarolinska Institutet·JournalNature Communications·TypeExperimental study·DateDec 4, 2024

Anti-obesity drugs, lifestyle interventions show cardiovascular benefits beyond weight loss

Studies published in JACC found that anti-obesity drugs such as tirzepatide and semaglutide improved cardiac structure and function, as well as reduced cardiac risk biomarkers with lifestyle interventions. These findings suggest that these treatments may have a transformative impact on cardiovascular health beyond weight loss.

SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·DateNov 18, 2024

Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction

Prescription rates of sodium-glucose cotransporter-2 inhibitors increased substantially within 2 years after publication of clinical trial evidence documenting benefit. The study highlights the need to understand strategies used by higher prescribing centers to increase SGLT2i adoption.

SourceJAMA Network·JournalJAMA Cardiology·DateNov 18, 2024

Mass General Brigham researchers find too much sitting hurts the heart

A new study by Mass General Brigham researchers found that excessive sedentary behavior increases the risk of heart failure and cardiovascular death. Even among individuals who meet guideline levels of moderate-to-vigorous physical activity, sitting for extended periods can still pose significant health risks. The study's findings sugg...

SourceMass General Brigham·JournalJournal of the American College of Cardiology·TypeObservational study·DateNov 15, 2024

London Health Sciences Centre first in Canada to implant cutting edge cardioverter defibrillator

The London Health Sciences Centre was the first and only hospital in Canada to implant a new extravascular implantable cardioverter defibrillator (ICD) during clinical trials. The device has been shown to provide long-term safety, efficacy, and performance, offering better comfort and care for patients.

SourceLondon Health Sciences Centre Research Institute·TypeRandomized controlled/clinical trial·DateNov 13, 2024

While more is better, even moderate amounts of exercise may reduce risk for common heart condition

A new study found that even moderate amounts of exercise can reduce the risk of atrial fibrillation, a common heart condition. The research, led by NYU Langone Health, used data from over 6,000 participants and showed that those with higher physical activity levels had a lower risk of developing the condition.

Plastic device aids robot-assisted heart surgery

A new plastic device has been developed to secure the surgical field during robot-assisted heart surgery, allowing surgeons to operate with greater independence. The device, made from a type of plastic used in medical implants and aerospace industry, expands to a certain size and retains its shape.

SourceOsaka Metropolitan University·JournalInnovations Technology and Techniques in Cardiothoracic and Vascular Surgery·TypeCase study·DateNov 7, 2024

After a heart attack, the heart signals to the brain to increase sleep to promote healing

A new study found that the heart sends signals to the brain to increase sleep after a heart attack, promoting healing and reducing inflammation. This communication between the heart and brain is mediated through the immune system and can lead to improved recovery and reduced risk of further cardiovascular events.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature·TypeRandomized controlled/clinical trial·DateOct 30, 2024

Cardiovascular risk biomarkers in inflammaging

Researchers propose a comprehensive biomarker-based approach to assess cardiovascular risk by combining markers of chronic inflammation with cardiac health indicators. This approach reveals the significant impact of aging-related inflammation, or 'inflammaging,' on heart health and opens new avenues for targeted interventions.

SourceImpact Journals LLC·JournalAging-US·TypeCommentary/editorial·DateOct 29, 2024

Heart failure mortality declining in Sweden

A new study from Karolinska Institutet reveals a decline in heart failure mortality in Sweden over the last 20 years. Despite improvements, the prognosis for heart failure patients remains concerning, with 25% of those diagnosed in 2022 dying within a year.

SourceKarolinska Institutet·JournalEuropean Journal of Heart Failure·DateOct 28, 2024

A new image processing strategy for cardiac magnetic resonance imaging identifies culprit areas underlying complex tachycardias

A new image processing strategy for cardiac magnetic resonance imaging identifies areas responsible for complex ventricular tachycardias, enabling preoperative planning and reducing procedure times and complications. The systematic approach eliminates operator bias and increases sensitivity for detecting these regions.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalEP Europace·TypeRandomized controlled/clinical trial·DateOct 8, 2024

Presence of subclinical atherosclerosis is marker of mortality and its progression increases risk of death

A new study published in the Journal of the American College of Cardiology found that subclinical atherosclerosis is independently associated with the risk of dying from any cause. The study also showed that monitoring the progression of atherosclerosis can improve the prediction and prevention of death from any cause.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateSep 30, 2024

Estimated long-term benefits of finerenone in heart failure

Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone is estimated to extend event-free survival by up to 3 years among people with heart failure. The FINEARTS-HF randomized clinical trial found this benefit in patients with mildly reduced or preserved ejection fraction.

SourceJAMA Network·JournalJAMA Cardiology·DateSep 27, 2024